A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study ...

Immunotherapy drugs like dostarlimab have been used as a front-line treatment for some metastatic cancers, melanoma, and other cancer types. Dostarlimab was first approved for use in endometrial ...

Matulonis, MD, discusses preliminary efficacy and safety results for puxitatug samrotecan in patients with recurrent endometrial cancer ... had received prior immunotherapy,” Matulonis, chief ...

The verdict of the US district court in New Jersey is that Shilpa's generic infringes a US patent on multikinase inhibitor ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Imfinzi be used in combination with ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse ... an FDA filing in second-line endometrial cancer later this year. The drug is being tested ...

Welcome to The Pharma Letter ’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...